Osteoporosis
Conference Coverage
Take drug, patient-level factors into account for when to end antiresorptive therapy
LAS VEGAS – The agent and individual patient factors may affect the duration of treatment and the approach to resuming therapy.
Conference Coverage
Don’t let knowledge gaps hold back fracture prevention efforts, experts say
ORLANDO – Experts recommend focusing on what is already known to prevent osteoporotic fractures to avoid inaction because of lack of knowledge in...
Conference Coverage
Multiple zoledronic acid doses may be needed after stopping denosumab
ORLANDO – An ongoing, randomized study finds that after 1 year about one-third of patients with osteopenia have needed readministration of...
Conference Coverage
Much work to be done in optimizing treatment for transgender children
ORLANDO – Concerns include when to start gender-affirming sex hormones and their effect on bone mineral density.
Conference Coverage
Romosozumab benefits prevail, despite renal insufficiency
ORLANDO – Romosozumab (Evenity) did not noticeably affect increases in BMD or lowered vertebral fracture incidence among patients with various...
Conference Coverage
Consider cognitive reframing of osteoporosis to improve adherence
ORLANDO – Counter negative patient perceptions about osteoporosis treatment by explaining the risks of treatment with medications as well as the...
Conference Coverage
Osteoporosis remains a costly burden to older U.S. adults
ORLANDO – Older women and minorities continue to bear the brunt of the burden of fragility fractures in the United States.
Expert Commentary
Can we discern optimal long-term osteoporosis treatment for women?
The use of osteoporosis drugs in sequence—rather than a single agent for a long time—may be the most effective management...
Conference Coverage
Older black women have worse outcomes after fragility fracture
ORLANDO – Black women had a significantly higher mortality rate after a fracture, compared with their white counterparts.
Conference Coverage
Lumbar spine BMD, bone strength benefits persist after romosozumab-to-alendronate switch
ORLANDO – The effects occurred as early as month 6 and were sustained beyond 12 months after the transition to alendronate.
Conference Coverage
Vitamin D does not improve bone density, structure in healthy patients
ORLANDO – Daily use for 2 years did not affect areal BMD in the whole body, femoral neck, total hip, or spine, or...